Novel applications for serum procalcitonin testing in clinical practice

Procalcitonin has been widely studied as a biomarker for bacterial infections in hospitalized patients. It has been integrated into clinical guidelines to help reduce unnecessary antibiotic prescriptions. However, its reliability in patients with compromised organ function remains unclear. Prior research has shown that procalcitonin levels can rise in non-infectious conditions, which complicates its interpretation. This uncertainty limits its utility in certain patient populations. No prior work has fully resolved how procalcitonin behaves in patients with chronic or end-stage organ dysfunction. That uncertainty drives the need for a focused review of current evidence. This gap motivated the authors to examine the role of procalcitonin in non-infectious and organ-compromised settings. The goal is to clarify its diagnostic and prognostic potential beyond bacterial infection detection.

The purpose of this review is to evaluate the role of procalcitonin testing in patients with organ dysfunction. It aims to clarify how procalcitonin behaves in non-infectious conditions and in those with chronic diseases. The authors focus on populations with end-stage renal disease, heart failure, COPD, and cirrhosis. They also examine its use in post-surgical complications and neurological conditions. The review addresses the limitations of current clinical algorithms that rely on procalcitonin. It seeks to identify scenarios where procalcitonin may still be useful despite organ dysfunction. The study highlights the need for tailored interpretation of results in complex patient groups. This work aims to inform future diagnostic strategies and clinical decision-making in these populations.

The authors conducted a narrative review of published literature on procalcitonin in organ dysfunction and non-infectious diseases. They focused on studies involving patients with end-stage renal disease, congestive heart failure, COPD, and cirrhosis. They also examined research on procalcitonin in post-surgical anastomotic leaks and intracerebral hemorrhage. The review included analysis of diagnostic accuracy, prognostic value, and clinical utility. The authors synthesized findings from observational and cohort studies. They evaluated how procalcitonin levels correlate with disease progression and outcomes. The review excluded animal studies and in vitro experiments. The findings are presented thematically to highlight patterns and limitations in current evidence.

Procalcitonin levels may rise in non-infectious conditions such as post-surgical anastomotic leaks and acute kidney injury. In patients with end-stage renal disease, procalcitonin values may be falsely elevated. This complicates its use in guiding antibiotic decisions. In COPD exacerbations, procalcitonin may not reliably distinguish bacterial from viral causes. For heart failure patients, procalcitonin may reflect systemic inflammation rather than infection. In cirrhosis, procalcitonin levels may be unreliable due to altered metabolism. The review found that procalcitonin may still be useful in some non-infectious contexts when interpreted carefully. The strongest evidence supports its use in predicting complications after intracerebral hemorrhage. These findings suggest a need for context-specific interpretation of procalcitonin values.

The authors conclude that procalcitonin may have diagnostic and prognostic value in non-infectious conditions when interpreted with caution. They suggest that its use in patients with organ dysfunction requires adjustment for baseline physiology. The review highlights the need for further studies to define thresholds for procalcitonin in specific populations. The authors propose that procalcitonin may help identify post-surgical complications and neurological outcomes. They emphasize that current algorithms may not apply to patients with chronic organ dysfunction. The findings suggest that procalcitonin should not be used in isolation but in conjunction with clinical context. The authors call for more research to clarify its role in non-infectious disease management. These conclusions align with the evidence presented in the literature reviewed.